Proc Am Thorac Soc. 2012 Dec;9(5):269-73. doi: 10.1513/pats.201208-062ST.
Professional societies, like many other organizations around the world, have recognized the need to use more rigorous processes to ensure that healthcare recommendations are informed by the best available research evidence with input from appropriate stakeholders. This is the ninth of a series of 14 articles that were prepared by an international panel to advise guideline developers in respiratory and other diseases on approaches for guideline development. We updated a review of the literature on stakeholder involvement, focusing on six key questions.
In this review we addressed the following questions. (1) What are "stakeholders"? (2) Why involve stakeholders in guidelines? (3) At what stage should stakeholders contribute to guidelines? (4) What are the potential barriers to integrating stakeholder involvement? (5) How can stakeholders be involved effectively? (6) Should anyone be excluded from the process? We searched PubMed and other databases of methodological studies for existing systematic reviews and relevant methodological research. We did not conduct our own systematic reviews. Our conclusions are based on available evidence, the experience of guideline developers, and workshop discussions.
Stakeholders are all those who have a legitimate interest in a guideline. They include healthcare professionals, patients and caregivers, public and private funding bodies, managers, employers, and manufacturers. Their engagement is justified for several reasons, including limitations of evidence, principles of transparency and democracy, ownership, and potential policy implications. They have a role to play at different points of guideline development, but their involvement can be complex. To be successful, stakeholder engagement needs to be inclusive, equitable, and adequately resourced.
专业协会与世界各地的许多其他组织一样,已经认识到需要使用更严格的流程来确保医疗保健建议基于最佳可用研究证据,并征求适当利益相关者的意见。这是由一个国际小组为呼吸和其他疾病的指南制定者提供建议的 14 篇系列文章中的第 9 篇。我们更新了一份关于利益相关者参与的文献综述,重点关注六个关键问题。
在本次综述中,我们回答了以下问题。(1)什么是“利益相关者”?(2)为什么要让利益相关者参与指南制定?(3)利益相关者应在何时为指南做出贡献?(4)整合利益相关者参与的潜在障碍有哪些?(5)如何有效地让利益相关者参与进来?(6)是否应该排除任何人?我们在 PubMed 和其他方法学研究数据库中搜索了现有的系统评价和相关方法学研究。我们没有进行自己的系统评价。我们的结论基于现有证据、指南制定者的经验和研讨会讨论。
利益相关者是指所有对指南有合法利益的人。他们包括医疗保健专业人员、患者和护理人员、公共和私人资助机构、管理者、雇主和制造商。让他们参与有几个原因,包括证据的局限性、透明度和民主原则、所有权以及潜在的政策影响。他们在指南制定的不同阶段都有作用,但他们的参与可能很复杂。为了取得成功,利益相关者的参与需要具有包容性、公平性和充足的资源。